Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients
Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients
Recruiting · NCT03127267 · Registry updated 2025-09-12Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients | Nutritional and Metabolic Diseases, TDP-43 proteinopathy, amyotrophic lateral sclerosis, central nervous system disorder, metabolic disease, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, spinal cord disorder | Recruiting | Phase 3 | 2025-09-12 | NCT03127267 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| AB Science | 5 |
56 results · Page 1 of 3
Research sites
Swipe the table sideways for more columns.